低剂量吉西他滨联合顺铂治疗老年晚期非小细胞肺癌临床观察.docVIP

低剂量吉西他滨联合顺铂治疗老年晚期非小细胞肺癌临床观察【摘要】 目的观察低剂量吉西他滨联合顺铂治疗老年晚期非小细胞肺癌的疗效及毒副反应。方法 国产吉西他滨 800 mg/m?2,静脉滴注30 min,第1、8天;顺铂14 mg/m?2,第1~5天,3周重复,治疗32例70岁以上的晚期非小细胞肺癌患者。结果 32例患者共化疗108周期,完全缓解0,部分缓解17例(53.1%,17/32),稳定8例(25%,8/32),进展7例(21.9%,7/32),总有效率53.1%,疾病控制率(CR+PR+SD)78.1%,中位疾病进展时间5.2个月,中位生存期11.6个月。毒副作用主要为粒细胞减少、血小板下降、贫血、乏力。均可耐受。结论 低剂量吉西他滨联合顺铂治疗老年晚期非小细胞肺癌的疗效肯定且患者耐受性较好。 【关键词】非小细胞肺癌;老年患者;吉西他滨;顺铂;低剂量 Observation of low-dose Gemcitabine combined with Cisplatin in treating elderly patients with non-small-celllungcancer ZHANG Chun-zhen ,SHI Chao-sheng ,XIA Jin.Medical-department of Anyang Tumor Hospital, Anyang 455000,China 【Abstract】 Objective To evaluate the efficacy and toxicity of low-dose gemcitabine combined with cisplatin in elderly patients with advanced non-small-cell lung cancer. Methods Thirty-two elderly patients with advanced non-small-cell lung cancer were treated with gemcitabine 800 mg/m?2 ond1、8,cisplatin 14 mg/m?2on d1-5.The regimen was repeated every 21 days. All patients received two or more cycles.Results Thirty-two patients were evaluated after 2 to 6 cycles of chemotherapy. None achieved CR and 17 cases achieved PR.The overall response rate (ORR)was 53.1% and the disease control rate(DCR) was 78.1%.The median time to progression (TTP) was 5.2 months, and median overal survival(OS) was 11.6 months.The most common toxicities were: neutropenia, thrombocytopenia,anaemiaand fatigue.These toxicities were well-tolerated.Conclusion The regimen of low-dose gemcitabine combined with cisplatinis active and well toleratedin treating elderly patients with advanced NSCLC. 【Key words】 NSCLC ; The elderly; Gemcitabine; Cisplatin;Low-dose 作者单位:455000安阳市肿瘤医院内科 目前,肺癌仍是肿瘤死亡的主要原因,其中非小细胞肺癌占全部肺癌的80%,预后不佳,5年的生存率在30%左右。随着人口的老龄化,老年人患肺癌的几率逐渐增加。由于老年人的生理特性及多数合并有其他慢性疾病,选择合适的化疗方案显得尤为重要。本科于2006年5月至2008年12月,采用吉西他滨联合低剂量顺铂治疗70岁以上患者32例,疗效较好,现报告如下。 1 资料与方法 1.1 资料 全组32例患者,年龄≥70岁,中位年龄74.3岁,均经病理证实的非小细胞肺癌,均为IIIa-IV期,具有可测量病灶。其中男21例,女11例,IIIa期2例,IIIb期6例,IV期24例,PS评分0~2分。预计生存期大于3个月,化